LaserNCT05811026
Efficacy of Periorbital Rejuvenation With a 1927 nm Diode Laser Treatment
A study testing Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval) and Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval) in people with Laser and Periorbital, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
The purpose of this research project is to investigate the treatment design, therapeutic effects and safety of the 1927 nm laser for the rejuvenation of the skin around the eyes. Read more about this study
- Who is it for?
- Ages 30 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Laser, Periorbital
- What is being tested?
- Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval) and Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteTaiwan
- Study dates
- 15 Mar 2023to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- aged between 30 and 65 years old;
- no significant skin lesions or inflammation on the facial skin;
- willing and able to comply with study requirements, instructions, and restrictions;
- signed informed consent form.
Who cannot join
- underwent facial active treatment, such as using laser, intense pulsed light, radiofrequency skin tightening, ultrasound skin tightening, botulinum toxin, or dermal fillers injection, within the previous six months;
- have chronic skin diseases such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo, rosacea, or keloid;
- pregnant or breastfeeding;
- suffered from acute illnesses or infections requiring treatment within 14 days before entering the study;
- have had serious illnesses (such as heart disease, lung disease, brain disease, or liver disease) within the previous three months;
- allergic to Lidocaine or Prilocaine used in topical anesthetic cream or suffer from methemoglobinemia;
- used any skin medication on the face within 30 days before the trial, deemed by the principal investigator to affect the study results;
- deemed unsuitable for the study by the principal investigator.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-Label, Single Center Clinical Study to Evaluate the Efficacy of Periorbital Rejuvenation With a 1927 nm Diode Laser Treatment
The purpose of this research project is to investigate the treatment design, therapeutic effects and safety of the 1927 nm laser for the rejuvenation of the skin around the eyes.
Read the detailed description
The chromophore of the 1927 nm diode laser is mainly water, which can be used for skin rejuvenation. This study intends to use the Solta CLEAR+BRILLIANT Laser System, featuring a 1927 nm diode laser with 5 mJ energy, a treatment spot of 140 μm, a treatment depth of 170 μm, and a treatment coverage of approximately 5% per energy level after four rounds of treatment using the patented Intelligent Optical Tracking® System (IOTs). The purpose of this research project is to investigate the treatment design, therapeutic effects and safety of the 1927 nm laser for the rejuvenation of the skin around the eyes. This is an open-label, single-center clinical trial. Participants will be randomized into treatment groups, including Group A (treatment interval of 2 weeks) or Group B (treatment interval of 4 weeks).
- Conditions
- Laser, Periorbital
- Being tested
- Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval), Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)
- Keywords
- 1927 nm, periorbital rejuvenation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)Device
- Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment
- Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment
- Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment
- Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed
Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)Device
- Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment
- Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment
- Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment
- Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed
| Study group | Role | What they receive |
|---|---|---|
| Arm A: 2-week interval between treatments | Experimental | The interval between the first, second, and third treatments in this arm is two weeks, and the follow-up session will take place four weeks after the third treatment. Receives: Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval) |
| Arm B: 4-week interval between treatments | Experimental | The interval between the first, second, and third treatments in this arm is four weeks, and the follow-up session will take place four weeks after the third treatment. Receives: Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Texture Score at Visit 4 (End-of-study Session)
The texture score is a parameter measured by the Antera 3D system, calculated based on average roughness (Ra [μm]). Ra roughness, or average roughness, is a standard metric used to describe surface smoothness. It represents the average height of microscopic peaks and valleys on the skin surface. The Ra [μm] values range from 0 to infinity.
To interpret the texture score, skin surface roughness is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate poorer skin texture. The overall texture score ranges from 0 to infinity.
Change from baseline in texture score at Visit 4 = texture score at Visit 4 - texture score at baseline
Measured: Group A: baseline and week 8; Group B: baseline and week 12
Secondary outcomes (21)
Change From Baseline in Color Measurements (L*) at Visit 4 (End-of-study Session)
In the CIELAB color space, the L* value represents the lightness of a color, indicating how light or dark it appears. The scale ranges from 0 (black) to 100 (white), providing a standardized measure of brightness that aligns with human visual perception. This metric is particularly useful in assessing skin tone. The average L* value within a region of interest was calculated at each visit.
Change from baseline in L* at Visit 4 = L* at Visit 4 - L* at baseline
Measured: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Pigmentation Score at Visit 4 (End-of-study Session)
The pigmentation score is a parameter measured by the Antera 3D system, calculated based on the variation (arbitrary units) and average level (arbitrary units). Variation (arbitrary units) indicates mean value within the region of interest of all deviations from the pigmentation average level in absolute value. Average level (arbitrary units) indicates the average concentration of pigmentation in the region of interest. To interpret the pigmentation score, skin pigmentation is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate poorer pigmentation conditions. The overall pigmentation score ranges from 0 to infinity.
Change from baseline in pigmentation score at Visit 4 = pigmentation score at Visit 4 - pigmentation score at baseline
Measured: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Pores' Index at Visit 4 (End-of-study Session)
The pores' index is an overall score representing skin porosity within the selected region of interest. It incorporates pore depth, size, and density-condensed into a single parameter. This index is particularly useful for the global evaluation of porosity reduction in before-and-after comparisons.
Formula: Index = (V / S) × 1000 V = total volume of pores in the selected area (mm³) S = selected area (mm²)
Change from baseline in pores' index at Visit 4 = pores' index at Visit 4-pores' indexe at baseline
Measured: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Wrinkles' Score at Visit 4 (End-of-study Session)
The wrinkle score is a parameter measured by the Antera 3D system, calculated based on the indentation index (μm). The indentation index (μm) represents the average depth of all points or dents below the surface level. The indentation index (μm) values range from 0 to infinity.
To interpret the wrinkle score, skin damage is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate more severe wrinkle conditions. The overall wrinkle score ranges from 0 to infinity.
Change from baseline in wrinkles' score at Visit 4 = wrinkles' score at Visit 4 - wrinkles' score at baseline
Measured: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Physician Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 4 (End-of-study Session)
Global Aesthetic Improvement Score (GAIS) is a standardized 5-point scale used to assess overall aesthetic improvement following a cosmetic treatment. It ranges as follows: 5 - Very Much Improved, 4 - Much Improved, 3 - Improved, 2 - No Change, 1 - Worse Physician Assessment of GAIS refers to the GAIS score evaluated by the physician.
Change from Baseline in Physician Assessment of GAIS at Visit 4 is defined as the GAIS score assessed at Visit 4 in comparison to baseline.
Measured: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Patient Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 4 (End-of-study Session)
Global Aesthetic Improvement Score (GAIS) is a standardized 5-point scale used to assess overall aesthetic improvement following a cosmetic treatment. It ranges as follows: 5 - Very Much Improved, 4 - Much Improved, 3 - Improved, 2 - No Change, 1 - Worse Patient Assessment of GAIS refers to the GAIS score evaluated by the patient. Change from Baseline in Patient Assessment of GAIS at Visit 4 is defined as the GAIS score assessed at Visit 4 in comparison to baseline.
Measured: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Texture Score at Visit 2
The texture score is a parameter measured by the Antera 3D system, calculated based on average roughness (Ra [μm]). Ra roughness, or average roughness, is a standard metric used to describe surface smoothness. It represents the average height of microscopic peaks and valleys on the skin surface. The Ra [μm] values range from 0 to infinity.
To interpret the texture score, skin surface roughness is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate poorer skin texture. The overall texture score ranges from 0 to infinity.
Change from baseline in texture score at Visit 2 = texture score at Visit 2 - texture score at baseline
Measured: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Color Measurements (L*) at Visit 2
In the CIELAB color space, the L* value represents the lightness of a color, indicating how light or dark it appears. The scale ranges from 0 (black) to 100 (white), providing a standardized measure of brightness that aligns with human visual perception. This metric is particularly useful in assessing skin tone. The average L* value within a region of interest was calculated at each visit.
Change from baseline in L* at Visit 2 = L* at Visit 2 - L* at baseline
Measured: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Pigmentation Score at Visit 2
The pigmentation score is a parameter measured by the Antera 3D system, calculated based on the variation (arbitrary units) and average level (arbitrary units). Variation (arbitrary units) indicates mean value within the region of interest of all deviations from the pigmentation average level in absolute value. Average level (arbitrary units) indicates the average concentration of pigmentation in the region of interest. To interpret the pigmentation score, skin pigmentation is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate poorer pigmentation conditions. The overall pigmentation score ranges from 0 to infinity.
Change from baseline in pigmentation score at Visit 2 = pigmentation score at Visit 2 - pigmentation score at baseline
Measured: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Pores' Index at Visit 2
The pores' index is an overall score representing skin porosity within the selected region of interest. It incorporates pore depth, size, and density-condensed into a single parameter. This index is particularly useful for the global evaluation of porosity reduction in before-and-after comparisons.
Formula: Index = (V / S) × 1000 V = total volume of pores in the selected area (mm³) S = selected area (mm²)
Change from baseline in pores' index at Visit 2 = pores' index at Visit 2 - pores' index at baseline
Measured: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Wrinkles' Score at Visit 2
The wrinkle score is a parameter measured by the Antera 3D system, calculated based on the indentation index (μm). The indentation index (μm) represents the average depth of all points or dents below the surface level. The indentation index (μm) values range from 0 to infinity.
To interpret the wrinkle score, skin damage is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate more severe wrinkle conditions. The overall wrinkle score ranges from 0 to infinity.
Change from baseline in wrinkles' score at Visit 2 = wrinkles' score at Visit 2 - wrinkles' score at baseline
Measured: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Physician Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 2
Global Aesthetic Improvement Score (GAIS) is a standardized 5-point scale used to assess overall aesthetic improvement following a cosmetic treatment. It ranges as follows: 5 - Very Much Improved, 4 - Much Improved, 3 - Improved, 2 - No Change, 1 - Worse Physician Assessment of GAIS refers to the GAIS score evaluated by the physician.
Change from Baseline in Physician Assessment of GAIS at Visit 2 is defined as the GAIS score assessed at Visit 2 in comparison to baseline.
Measured: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Patient Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 2
Global Aesthetic Improvement Score (GAIS) is a standardized 5-point scale used to assess overall aesthetic improvement following a cosmetic treatment. It ranges as follows: 5 - Very Much Improved, 4 - Much Improved, 3 - Improved, 2 - No Change, 1 - Worse Patient Assessment of GAIS refers to the GAIS score evaluated by the patient. Change from Baseline in Patient Assessment of GAIS at Visit 2 is defined as the GAIS score assessed at Visit 2 in comparison to baseline.
Measured: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Texture Score at Visit 3
The texture score is a parameter measured by the Antera 3D system, calculated based on average roughness (Ra [μm]). Ra roughness, or average roughness, is a standard metric used to describe surface smoothness. It represents the average height of microscopic peaks and valleys on the skin surface. The Ra [μm] values range from 0 to infinity.
To interpret the texture score, skin surface roughness is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate poorer skin texture. The overall texture score ranges from 0 to infinity.
Change from baseline in texture score at Visit 3 = texture score at Visit 3 - texture score at baseline
Measured: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Color Measurements (L*) at Visit 3
In the CIELAB color space, the L* value represents the lightness of a color, indicating how light or dark it appears. The scale ranges from 0 (black) to 100 (white), providing a standardized measure of brightness that aligns with human visual perception. This metric is particularly useful in assessing skin tone. The average L* value within a region of interest was calculated at each visit.
Change from baseline in L* at Visit 3 = L* at Visit 3 - L* at baseline
Measured: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Pigmentation Score at Visit 3
The pigmentation score is a parameter measured by the Antera 3D system, calculated based on the variation (arbitrary units) and average level (arbitrary units). Variation (arbitrary units) indicates mean value within the region of interest of all deviations from the pigmentation average level in absolute value. Average level (arbitrary units) indicates the average concentration of pigmentation in the region of interest. To interpret the pigmentation score, skin pigmentation is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate poorer pigmentation conditions. The overall pigmentation score ranges from 0 to infinity.
Change from baseline in pigmentation score at Visit 3 = pigmentation score at Visit 3 - pigmentation score at baseline
Measured: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Pores' Index at Visit 3
The pores' index is an overall score representing skin porosity within the selected region of interest. It incorporates pore depth, size, and density-condensed into a single parameter. This index is particularly useful for the global evaluation of porosity reduction in before-and-after comparisons.
Formula: Index = (V / S) × 1000 V = total volume of pores in the selected area (mm³) S = selected area (mm²)
Change from baseline in pores' index at Visit 3 = pores' index at Visit 3 - pores' index at baseline
Measured: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Wrinkles' Score at Visit 3
The wrinkle score is a parameter measured by the Antera 3D system, calculated based on the indentation index (μm). The indentation index (μm) represents the average depth of all points or dents below the surface level. The indentation index (μm) values range from 0 to infinity.
To interpret the wrinkle score, skin damage is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate more severe wrinkle conditions. The overall wrinkle score ranges from 0 to infinity.
Change from baseline in wrinkles' score at Visit 3 = wrinkles' score at Visit 3 - wrinkles' score at baseline
Measured: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Physician Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 3
Global Aesthetic Improvement Score (GAIS) is a standardized 5-point scale used to assess overall aesthetic improvement following a cosmetic treatment. It ranges as follows: 5 - Very Much Improved, 4 - Much Improved, 3 - Improved, 2 - No Change, 1 - Worse Physician Assessment of GAIS refers to the GAIS score evaluated by the physician.
Change from Baseline in Physician Assessment of GAIS at Visit 3 is defined as the GAIS score assessed at Visit 3 in comparison to baseline.
Measured: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Patient Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 3
Global Aesthetic Improvement Score (GAIS) is a standardized 5-point scale used to assess overall aesthetic improvement following a cosmetic treatment. It ranges as follows: 5 - Very Much Improved, 4 - Much Improved, 3 - Improved, 2 - No Change, 1 - Worse Patient Assessment of GAIS refers to the GAIS score evaluated by the patient. Change from Baseline in Patient Assessment of GAIS at Visit 3 is defined as the GAIS score assessed at Visit 3 in comparison to baseline.
Measured: Group A: baseline and week 4; Group B: baseline and week 8
Visual Analogue Scale (VAS) During Treatment
The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires, which a higher score suggests greater pain intensity. It ranges from 0 to 10 in increments of 1. A score of 0 cm indicates "no pain" and 10 indicates "worst pain imaginable".
Measured: Group A: week 0; Group B: week 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2023
- Study start15 Mar 2023
- Primary completion21 Jun 2023
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for LaserStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- BRIDGECON CO,.LTD.
- Responsible party
- Sponsor
- Investigators
- Yi-Hua Liao, MD/PhD, Study chair, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05811026
- Sponsor's protocol ID
- 202207219DSC
- Status last verified
- Mar 2025
- First submitted
- 13 Mar 2023
- Last updated
- 18 Jun 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Single Center Clinical Study to Evaluate the Efficacy of Periorbital Rejuvenation With a 1927 nm Diode Laser Treatment
- ClinicalTrials.gov ID
- NCT05811026
- Acronym / sponsor ID
- 202207219DSC
- Conditions
- Laser, Periorbital
- Keywords
- 1927 nm, periorbital rejuvenation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Collaborators
- BRIDGECON CO,.LTD.
- Study start
- 15 Mar 2023 (actual)
- Primary completion
- 21 Jun 2023 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 13 Apr 2023 (actual)
- Results
- Posted 18 Jun 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research project is to investigate the treatment design, therapeutic effects and safety of the 1927 nm laser for the rejuvenation of the skin around the eyes.
Detailed description
The chromophore of the 1927 nm diode laser is mainly water, which can be used for skin rejuvenation. This study intends to use the Solta CLEAR+BRILLIANT Laser System, featuring a 1927 nm diode laser with 5 mJ energy, a treatment spot of 140 μm, a treatment depth of 170 μm, and a treatment coverage of approximately 5% per energy level after four rounds of treatment using the patented Intelligent Optical Tracking® System (IOTs). The purpose of this research project is to investigate the treatment design, therapeutic effects and safety of the 1927 nm laser for the rejuvenation of the skin around the eyes. This is an open-label, single-center clinical trial. Participants will be randomized into treatment groups, including Group A (treatment interval of 2 weeks) or Group B (treatment interval of 4 weeks).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A: 2-week interval between treatments | Experimental | Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)The interval between the first, second, and third treatments in this arm is two weeks, and the follow-up session will take place four weeks after the third treatment. |
| Arm B: 4-week interval between treatments | Experimental | Device: Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)The interval between the first, second, and third treatments in this arm is four weeks, and the follow-up session will take place four weeks after the third treatment. |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- aged between 30 and 65 years old;
- no significant skin lesions or inflammation on the facial skin;
- willing and able to comply with study requirements, instructions, and restrictions;
- signed informed consent form.
Key exclusion criteria (8 listed)
- underwent facial active treatment, such as using laser, intense pulsed light, radiofrequency skin tightening, ultrasound skin tightening, botulinum toxin, or dermal fillers injection, within the previous six months;
- have chronic skin diseases such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo, rosacea, or keloid;
- pregnant or breastfeeding;
- suffered from acute illnesses or infections requiring treatment within 14 days before entering the study;
- have had serious illnesses (such as heart disease, lung disease, brain disease, or liver disease) within the previous three months;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment * Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment * Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment * Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed | Device | Arm A: 2-week interval between treatments |
| Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment * Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment * Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment * Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed | Device | Arm B: 4-week interval between treatments |
Primary outcome
Change From Baseline in Texture Score at Visit 4 (End-of-study Session)
Time frame: Group A: baseline and week 8; Group B: baseline and week 12
The texture score is a parameter measured by the Antera 3D system, calculated based on average roughness (Ra [μm]). Ra roughness, or average roughness, is a standard metric used to describe surface smoothness. It represents the average height of microscopic peaks and valleys on the skin surface. The Ra [μm] values range from 0 to infinity. To interpret the texture score, skin surface roughness is categorized into five intervals: Mild: 0-25, Moderate: 25-50, Advanced: 50-75, Severe: 75-100, Very Severe: >100. Higher scores indicate poorer skin texture. The overall texture score ranges from 0 to infinity. Change from baseline in texture score at Visit 4 = texture score at Visit 4 - texture score at baseline
21 secondary outcomes
Change From Baseline in Color Measurements (L*) at Visit 4 (End-of-study Session)
Time frame: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Pigmentation Score at Visit 4 (End-of-study Session)
Time frame: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Pores' Index at Visit 4 (End-of-study Session)
Time frame: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Wrinkles' Score at Visit 4 (End-of-study Session)
Time frame: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Physician Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 4 (End-of-study Session)
Time frame: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Patient Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 4 (End-of-study Session)
Time frame: Group A: baseline and week 8; Group B: baseline and week 12
Change From Baseline in Texture Score at Visit 2
Time frame: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Color Measurements (L*) at Visit 2
Time frame: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Pigmentation Score at Visit 2
Time frame: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Pores' Index at Visit 2
Time frame: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Wrinkles' Score at Visit 2
Time frame: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Physician Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 2
Time frame: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Patient Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 2
Time frame: Group A: baseline and week 2; Group B: baseline and week 4
Change From Baseline in Texture Score at Visit 3
Time frame: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Color Measurements (L*) at Visit 3
Time frame: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Pigmentation Score at Visit 3
Time frame: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Pores' Index at Visit 3
Time frame: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Wrinkles' Score at Visit 3
Time frame: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Physician Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 3
Time frame: Group A: baseline and week 4; Group B: baseline and week 8
Change From Baseline in Patient Assessment of Global Aesthetic Improvement Score (GAIS), at Visit 3
Time frame: Group A: baseline and week 4; Group B: baseline and week 8
Visual Analogue Scale (VAS) During Treatment
Time frame: Group A: week 0; Group B: week 0
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Laser
Active, not recruiting
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
Skin Resurfacing
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
RecruitingPhase 4
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias
Telangiectasias, Reticular Veins
Not yet recruiting
Recurrent Aphthous Stomatitis Management in Children Using Diode Laser 980 Nanometer Versus Hyaluronic Acid Gel (RCT)
Apthous Ulcer
Not yet recruitingObservational study
Efficacy of Aflibercept (8 mg) With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm: Retrospective Study"
Retinal Arterial Macroaneurysm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yi-Hua Liao, MD/PhD study chair
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval) and Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval) in people with Laser and Periorbital, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 18 Jun 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Texture Score at Visit 4 (End-of-study Session) (time frame: Group A: baseline and week 8; Group B: baseline and week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2025.